详情页 - 聚合机构库演示平台

资源类型：

文章类型：

作者：

Song, Yuqin[1] * ; Gao, Quanli[2] ; Zhang, Huilai[3] ; Fan, Lei[4] ; Zhou, Jianfeng[5]

; Zou, Dehui[6,7] ; Li, Wei[8] ; Yang, Haiyan[9] ; Liu, Ting[10] ; Wang, Quanshun[11] ; Lv, Fangfang[12] ; Yang, Yu[13] ; Guo, Haiyi[14,15] ; Yang, Liudi[14,15] ; Elstrom, Rebecca[14,15] ; Huang, Jane[14,15] ; Novotny, William[14,15] ; Wei, Vivian[14,15] ; Zhu, Jun[1] ;

单位： [1]Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China [2]Zhengzhou Univ, Henan Canc Hosp, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China [3]Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China [4]Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Dept Hematol, Jiangsu Prov Hosp,Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China [5]Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Hubei, Peoples R China [6]Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China [7]Peking Union Med Coll, Tianjin, Peoples R China [8]Jilin Univ, Dept Hematol, Canc Ctr, Hosp 1, Tianjin, Peoples R China [9]Zhejiang Canc Hosp, Dept Oncol, Hangzhou, Zhejiang, Peoples R China [10]Sichuan Univ, Dept Hematol, West China Hosp, Chengdu, Sichuan, Peoples R China [11]Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China [12]Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China [13]Fujian Canc Hosp, Dept Lymphoma & HNC, Fuzhou, Fujian, Peoples R China [14]BeiGene Beijing Co Ltd, Beijing, Peoples R China [15]BeiGene USA Inc, San Mateo, CA USA

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区血液学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

JCR分区：

出版当年[2016]版：

Q1 HEMATOLOGY

最新[2023]版：

Q1 HEMATOLOGY

第一作者：

第一作者单位： [1]Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

文献详情